key: cord-0917434-0vtm046e
authors: Iwata, Hiroka; Kamiya, Koji; Kado, Soichiro; Nakaya, Takeo; Kawata, Hirotoshi; Komine, Mayumi; Ohtsuki, Mamitaro
title: Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination
date: 2021-09-17
journal: J Dermatol
DOI: 10.1111/1346-8138.16167
sha: 900cd15c5c38e52b08c8628fbc87a23732e54dbb
doc_id: 917434
cord_uid: 0vtm046e

nan

Vaccines are expected to prevent the onset and exacerbation of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report a rare case of immunoglobulin (Ig)A vasculitis following COVID-19 vaccination.

A 70-year-old woman presented with palpable purpura on her feet ( Figure 1a ). The purpura appeared on the toes and spread to the dorsum; vesicles and crusting were observed. There was no history of any antecedent infections, but she had a history of rheumatoid arthritis, which had been treated with adalimumab for 9 months. She had also received hemodialysis for 10 years. Two days before presenting to the clinic, she had received the second dose of the Pfizer-BioNTech 

Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 vaccine: an Italian single-centre case series

New-onset leukocytoclastic vasculitis after COVID-19 vaccine

Covid-19 related IgA vasculitis